Compare WVE & SPNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WVE | SPNT |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | Singapore | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | 2015 | N/A |
| Metric | WVE | SPNT |
|---|---|---|
| Price | $7.25 | $23.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 2 |
| Target Price | ★ $29.50 | $27.50 |
| AVG Volume (30 Days) | ★ 6.4M | 659.8K |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,704,000.00 | N/A |
| Revenue This Year | N/A | $0.85 |
| Revenue Next Year | $85.67 | $5.85 |
| P/E Ratio | ★ N/A | $5.65 |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $5.02 | $16.07 |
| 52 Week High | $21.73 | $23.66 |
| Indicator | WVE | SPNT |
|---|---|---|
| Relative Strength Index (RSI) | 34.60 | 63.90 |
| Support Level | $6.93 | $19.45 |
| Resistance Level | $7.67 | $23.42 |
| Average True Range (ATR) | 0.33 | 0.52 |
| MACD | 0.23 | 0.04 |
| Stochastic Oscillator | 47.80 | 75.00 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.